Autolus Therapeutics PLC (AUTL)
| Market Cap | 446.64M |
| Revenue (ttm) | 3.00M |
| Net Income (ttm) | -146.62M |
| Shares Out | 72.74M |
| EPS (ttm) | -2.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 147,736 |
| Open | 6.20 |
| Previous Close | 6.20 |
| Day's Range | 6.01 - 6.20 |
| 52-Week Range | 4.60 - 12.33 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 14.69 (+139.2%) |
| Est. Earnings Date | Nov 3, 2021 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therape...
Financial Performance
In 2020, AUTL's revenue was $1.72 million, a decrease of -41.02% compared to the previous year's $2.91 million. Losses were -$142.09 million, 14.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is 14.69, which is an increase of 139.21% from the latest price.
News
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
- Allowing global commercial launch capacity for obe-cel (AUTO1) - Allowing global commercial launch capacity for obe-cel (AUTO1)
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of...
BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its developm...
Autolus' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc's (NASDAQ: AUTL) AUTO1 (obecabtagene autoleuce...
Here's Why Autolus Therapeutics Is Surging Today
Potential licensing agreements with Moderna are giving investors reasons to cheer.
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the ...
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the W...
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatme...
LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...
Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort
Autolus Therapeutics plc (NASDAQ: AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and r/r Adult Acute Lymphobla...
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in ...
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells - - Data suggest that long term durab...
Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021
Attendance in person is not permitted
Autolus Therapeutics PLC Sponsored ADR (AUTL) Moves 35.5% Higher: Will This Strength Last?
Autolus Therapeutics PLC Sponsored ADR (AUTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into...
Why Autolus Therapeutics Stock Skyrocketed Today
The company announced encouraging clinical trial data for its experimental cell therapy, AUTO1.
Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Associa...
AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients
Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress
- Conference call to be held on May 6, 2021 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 6, 2021 at 8:30 am ET/1:30 pm BST -
Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor ...
LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman
LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...
Autolus Therapeutics to Participate in Investor Conferences Through April
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...
Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...
Autolus Therapeutics PLC Sponsored ADR (AUTL) Surges 6.5%: Is This an Indication of Further Gains?
Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the ...
Autolus Therapeutics Raises $100M Via Equity
Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for t...
Autolus Announces Pricing of Public Offering
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the ...